P53 mutation does not affect prognosis in ovarian epithelial malignancies.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• The p53 tumor suppressor gene is frequently mutated in human cancers, including ovarian cancer.
• Understanding the role of p53 mutations in ovarian cancer treatment response is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the association between p53 gene mutations and the efficacy of platinum-based chemotherapy in ovarian cancer patients.
• To determine if p53 mutation status correlates with overall survival, disease-free survival, and chemotherapy response.

Main Methods:

• DNA samples from tumor tissue and blood were collected from 73 ovarian cancer patients.
• Single-strand conformation polymorphism analysis and direct DNA sequencing of p53 exons 5-8 were performed.
• p53 mutation status was correlated with clinical outcomes, including survival and chemotherapy response.

Main Results:

• p53 mutations were detected in 44% of ovarian tumors and were more frequent in late-stage disease.
• No significant association was found between p53 status and overall survival or disease-free survival after chemotherapy.
• Tumors with p53 missense mutations showed significantly shorter recurrence times compared to those with normal p53.
• A trend suggested shorter disease-free survival for missense mutations versus non-missense mutations, but this was not statistically significant.

Conclusions:

• While p53 mutations are common in ovarian cancer, they do not predict overall response to platinum-based chemotherapy.
• p53 missense mutations may be associated with more aggressive disease progression and faster recurrence in ovarian cancer.